Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

Aaron C Tan,1 Tracy J Loh,2 Xue Lin Kwang,1 Gek San Tan,2 Kiat Hon Lim,2 Daniel SW Tan1 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore; 2Department of Pathology, Singapore General Hospital, Singapore, 169608, SingaporeCorrespondence: Daniel SW TanNation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	capmatinib met exon 14 skipping non-small cell lung cancer targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/031f63eddb764d4ebbf865c25b2d833d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:031f63eddb764d4ebbf865c25b2d833d
record_format	dspace
spelling	oai:doaj.org-article:031f63eddb764d4ebbf865c25b2d833d2021-12-02T14:13:58ZNovel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib1179-2728https://doaj.org/article/031f63eddb764d4ebbf865c25b2d833d2021-03-01T00:00:00Zhttps://www.dovepress.com/novel-therapies-for-metastatic-non-small-cell-lung-cancer-with-met-exo-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Aaron C Tan,1 Tracy J Loh,2 Xue Lin Kwang,1 Gek San Tan,2 Kiat Hon Lim,2 Daniel SW Tan1 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore; 2Department of Pathology, Singapore General Hospital, Singapore, 169608, SingaporeCorrespondence: Daniel SW TanNational Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, SingaporeTel +65 6436 8000Email daniel.tan.s.w@singhealth.com.sgAbstract: MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.Keywords: capmatinib, MET exon 14 skipping, non-small cell lung cancer, targeted therapyTan ACLoh TJKwang XLTan GSLim KHTan DSWDove Medical Pressarticlecapmatinibmet exon 14 skippingnon-small cell lung cancertargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 12, Pp 11-20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	capmatinib met exon 14 skipping non-small cell lung cancer targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	capmatinib met exon 14 skipping non-small cell lung cancer targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tan AC Loh TJ Kwang XL Tan GS Lim KH Tan DSW Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
description	Aaron C Tan,1 Tracy J Loh,2 Xue Lin Kwang,1 Gek San Tan,2 Kiat Hon Lim,2 Daniel SW Tan1 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore; 2Department of Pathology, Singapore General Hospital, Singapore, 169608, SingaporeCorrespondence: Daniel SW TanNational Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, SingaporeTel +65 6436 8000Email daniel.tan.s.w@singhealth.com.sgAbstract: MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.Keywords: capmatinib, MET exon 14 skipping, non-small cell lung cancer, targeted therapy
format	article
author	Tan AC Loh TJ Kwang XL Tan GS Lim KH Tan DSW
author_facet	Tan AC Loh TJ Kwang XL Tan GS Lim KH Tan DSW
author_sort	Tan AC
title	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_short	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_full	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_fullStr	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_full_unstemmed	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_sort	novel therapies for metastatic non-small cell lung cancer with met exon 14 alterations: a spotlight on capmatinib
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/031f63eddb764d4ebbf865c25b2d833d
work_keys_str_mv	AT tanac noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib AT lohtj noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib AT kwangxl noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib AT tangs noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib AT limkh noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib AT tandsw noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
_version_	1718391704659165184

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

Ejemplares similares